Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer(Universität Ulm), William G. Wierda(University of Maryland, Baltimore), Lang Zhou(Qingdao University), Steven Coutré(Georgetown University), Talha Munir(Leeds Teaching Hospitals NHS Trust), Clemens‐Martin Wendtner(Ludwig-Maximilians-Universität München), Sebastian Böttcher(University Hospital Schleswig-Holstein), Andrew W. Roberts(The Royal Melbourne Hospital), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Johannes Bloehdorn(Universitätsklinikum des Saarlandes), Ahmed Hamed Salem(Ain Shams University), Matthew S. Davids(Dana-Farber Cancer Institute), Brenda Chyla(AbbVie (United States)), Sarit Assouline(Jewish General Hospital), Anna Schuh(University of Oxford), Michael Hallek(Integrated Oncology (United States)), Jennifer A. Arzt(Universitätsklinikum des Saarlandes), John F. Seymour(The Royal Melbourne Hospital), Stephen P. Mulligan(Royal North Shore Hospital), Barbara Eichhorst(University of Cologne), Su Young Kim(Yonsei University), Wojciech Jurczak(Jagiellonian University), Gary Gordon, Johannes Schetelig(University Hospital Carl Gustav Carus), Maria Verdugo(AbbVie (United States)), Monali Desai(AbbVie (United States))
Cited by 313
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k